Cited by 478Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Kastelein, John J.P., van der Steeg, Wim A., Holme, Ingar, Gaffney, Michael, Cater, Nilo B., Barter, Philip, Deedwania, Prakash, Olsson, Anders G., Boekholdt, S. Matthijs, Demicco, David A., Szarek, Michael, LaRosa, John C., Pedersen, Terje R., Grundy, Scott M.·2008·Circulation

DOI 10.1161/circulationaha.107.713438

Open this paper in CoChat — free account

Abstract

BACKGROUND: Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy. METHODS AND RESULTS: A post hoc analysis was performed that combined data from 2 prospective, randomized clinical trials in which 10,001 ("Treating to New Targets") and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering") patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. In models with LDL cholesterol, non-HDL cholesterol and apolipoprotein B were positively associated with cardiovascular outcome, whereas a positive relationship with LDL cholesterol was lost. In a model that contained non-HDL cholesterol and apolipoprotein B, neither was significant owing to collinearity. Total/HDL cholesterol ratio and the apolipoprotein B/A-I ratio in particular were each more closely associated with outcome than any of the individual proatherogenic lipoprotein parameters. CONCLUSIONS: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol. Inclusion of measurements of the antiatherogenic lipoprotein fraction further strengthened the relationships. These data support the use of non-HDL cholesterol or apolipoprotein B as novel treatment targets for statin therapy. Given the absence of interventions that have been proven to consistently reduce cardiovascular disease risk through raising plasma levels of HDL cholesterol or apolipoprotein A-I, it seems premature to consider the ratio variables as clinically useful.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.713438

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Untitled work
(1996) · Cited by 6,884
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Global Burden of Cardiovascular Diseases
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 3,014
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548

Flagged first, then by citations

Show all 45 references

Research works printed but not linked: 5

10.1161/circ.104.22.2746 · DOI
10.1161/circ.101.5.477 · DOI
10.1161/circ.105.10.1162 · DOI
10.1161/circ.60.2.312704 · DOI
10.1161/circ.89.3.8124825 · DOI

Sorted by citations

Items 101–200 of 478

Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
Bosomworth, N. J. (2013) · Europe PMC (PubMed Central) · Cited by 54
A Review of Lipid Management in Primary and Secondary Prevention
Dembowski, E., & Davidson, M. H. (2009) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318192754e · Cited by 53
Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer
Lin, J., Xu, Z., Xie, J., Deng, X., Jiang, L., Chen, H., Peng, C., Li, H., Zhang, J., & Shen, B. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03985-1 · Cited by 52
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model
Hemingway, H., Henriksson, M., Chen, R., Damant, J., Fitzpatrick, N. K., Abrams, K. R., Hingorani, A. D., Janzon, M., Shipley, M. J., Feder, G. S., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14090 · Cited by 51
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 52
Comparison of Apolipoprotein B/A1 ratio, Framingham risk score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
Tian, M., Li, R., Shan, Z., Wang, D. W., Jiang, J., & Cui, G. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1144-y · Cited by 51
Revisiting the medication possession ratio threshold for adherence in lipid management
Watanabe, J. H., Bounthavong, M., & Chen, T. F. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.766164 · Cited by 53
Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol
Elshazly, M. B., Quispe, R., Michos, E. D., Sniderman, A. D., Toth, P. P., Banach, M., Kulkarni, K. R., Coresh, J., Blumenthal, R. S., Jones, S. R., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016163 · Cited by 50
A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
Ito, M. K. (2015) · PubMed Central · Cited by 49
Effects of Antarctic krill oil on lipid and glucose metabolism in C57BL/6J mice fed with high fat diet
Sun, D., Zhang, L., Chen, H., Feng, R., Cao, P., & Liu, Y. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0601-8 · Cited by 50
Correlation of Non–High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)
Grundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.018 · Cited by 47
Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study
Wongcharoen, W., Sutthiwutthichai, S., Gunaparn, S., & Phrommintikul, A. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0450-9 · Cited by 50
Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines
Virani, S. S., Woodard, L., Landrum, C. R., Pietz, K., Wang, D., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.023 · Cited by 46
The Present and Future of Lipid Testing in Cardiovascular Risk Assessment
Habeeb, N. W.-A., Higgins, V., Wolska, A. T., Delaney, S. R., Remaley, A. T., & Beriault, D. R. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad012 · Cited by 48
ApoB versus non-HDL-C: What to do when they disagree
Sniderman, A. D., Williams, K., & Cobbaert, C. M. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0054-2 · Cited by 45
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes
Browne, R. W., Weinstock‐Guttman, B., Horáková, D., Zivadinov, R., Bodziak, M. L., Tamano-Blanco, M., Badgett, D., Týblová, M., Vaněčková, M., Seidl, Z., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307106 · Cited by 46
Management of dyslipidemia in people with type 2 diabetes mellitus
Dunn, F. L. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9132-6 · Cited by 43
Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315639 · Cited by 43
Are You Targeting Non–High-Density Lipoprotein Cholesterol?
Robinson, J. G. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.056 · Cited by 44
Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis
de Gonzalo‐Calvo, D., Cenarro, A., Martínez-Bujidos, M., Badimón, L., Bayés‐Genís, A., Ordóñez‐Llanos, J., Civeira, F., & Llorente‐Cortés, V. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.085 · Cited by 46
Positive Relationship between Serum Low-Density Lipoprotein Cholesterol Levels and Visceral Fat in a Chinese Nondiabetic Population
Luo, Y., Ma, X., Shen, Y., Hao, Y., Hu, Y., Xiao, Y., Bao, Y., & Jia, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112715 · Cited by 44
Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2
Santos, R. D., Waters, D. D., Tarasenko, L. C., Messig, M., Jukema, J. W., Ferrières, J., Verdejo, J., & Chiang, C.-W. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.08.009 · Cited by 43
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
Jacobson, T. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0128 · Cited by 43
Effect of Atorvastatin vs. Rosuvastatin on Cardiac Sympathetic Nerve Activity in Non-Diabetic Patients With Dilated Cardiomyopathy
Tsutamoto, T., Sakai, H., 伊部, 邦., Yamaji, M., Kawahara, C., Nakae, I., Fujii, M., Yamamoto, T., & Horie, M. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0222 · Cited by 42
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)
Charlton-Menys, V., Betteridge, D. J., Colhoun, H. M., Fuller, J., France, M. W., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M. J., et al. (2008) · Diabetologia · doi:10.1007/s00125-008-1176-8 · Cited by 41
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events
Rubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
Marchioli, R., Levantesi, G., Silletta, M. G., Barlera, S., Bernardinangeli, M., Carbonieri, E., Cosmi, F., Franzosi, M. G., Latini, R., Lucci, D., et al. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.70 · Cited by 40
Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients
Ouchi, G., Komiya, I., Taira, S., Wakugami, T., & Ohya, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-021-01612-8 · Cited by 40
Lipids in health and disease
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 41
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.06.052 · Cited by 39
The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography
Song, Y., Yang, Y., Zhang, J., Wang, Y., He, W., Zhang, X. M., Zhu, J., & Lü, Z. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0155-6 · Cited by 39
Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study
Hwang, Y., Ahn, H. Y., Park, H., & Park, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0587-x · Cited by 38
Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis
Tamada, M., Makita, S., Abiko, A., Naganuma, Y., Nagai, M., & Nakamura, M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.009 · Cited by 38
Role of Berry Bioactive Compounds on Lipids and Lipoproteins in Diabetes and Metabolic Syndrome
Basu, A. (2019) · Nutrients · doi:10.3390/nu11091983 · Cited by 38
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Vitamin D Deficiency Associated With Markers of Cardiovascular Disease in Children With Obesity
Censani, M., Hammad, H. T., Christos, P. J., & Schumaker, T. (2018) · Global Pediatric Health · doi:10.1177/2333794x17751773 · Cited by 37
The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk
Walldius, G. (2012) · InTech eBooks · doi:10.5772/47869 · Cited by 36
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
Non-HDL C equals apolipoprotein B: except when it does not!
Sniderman, A. D., Williams, K., & Graaf, J. D. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ee80c · Cited by 34
Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events
Elshazly, M. B., Nicholls, S. J., Nissen, S. E., John, J. S., Martin, S. S., Jones, S. R., Quispe, R., Stegman, B., Kapadia, S. R., Tuzcu, E. M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.021 · Cited by 35
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol
Labenz, C., Prochaska, J. H., Huber, Y., Nagel, M., Straub, B. K., Wild, P. S., Galle, P. R., & Schattenberg, J. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1428 · Cited by 35
Relationship between Coronary Artery Disease and Non-HDL-C, and Effect of Highly Purified EPA on the Risk of Coronary Artery Disease in Hypercholesterolemic Patients Treated with Statins: Sub-Analysis of the Japan EPA Lipid Intervention Study (JELIS)
Sasaki, J., Yokoyama, M., Matsuzaki, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Itakura, H., Hishida, H., Kita, T., et al. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8326 · Cited by 35
Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial)
Grundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.003 · Cited by 33
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 33
Barriers to Non-HDL Cholesterol Goal Attainment by Providers
Virani, S. S., Steinberg, L., Murray, T. O., Negi, S., Nambi, V., Woodard, L., Bozkurt, B., Petersen, L. A., & Ballantyne, C. M. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.012 · Cited by 33
Lipoprotein Components and Risk of Congestive Heart Failure in 84 740 Men and Women in the Apolipoprotein MOrtality RISk Study (AMORIS)
Holme, I., AASTVEIT, A. H., Hammar, N., Jungner, I., & Walldius, G. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp129 · Cited by 33
Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management
Leon, A. S., & Bronas, U. G. (2009) · American Journal of Lifestyle Medicine · doi:10.1177/1559827609334518 · Cited by 34
Effects of Age, Sex, and Menopausal Status on Blood Cholesterol Profile in the Korean Population
Park, J. H., Lee, M. H., Shim, J., Choi, D. P., Song, B., Lee, S. W., Choi, H., & Kim, H. C. (2015) · Korean Circulation Journal · doi:10.4070/kcj.2015.45.2.141 · Cited by 33
Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects
Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181b0cf71 · Cited by 32
The effect of total cholesterol/high-density lipoprotein cholesterol ratio on mortality risk in the general population
Zhou, D., Liu, X., Lo, K. K.-H., Huang, Y., & Feng, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1012383 · Cited by 32
The effects of KaiXinSan on depression and its association with lipid profiles: A randomized, double-blinded, placebo-controlled trial
Hu, Y., Chen, C., Wang, Y., Yang, W., Wang, Y., Zhu, W., Yan, C., & Liu, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153467 · Cited by 31
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Yamaoka‐Tojo, M., Tojo, T., Kosugi, R., Hatakeyama, Y., Yoshida, Y., Machida, Y., Aoyama, N., Masuda, T., & Izumi, T. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-41 · Cited by 32
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Tunnicliffe, D. J., Palmer, S. C., Cashmore, B. A., Saglimbene, V. M., Krishnasamy, R., Lambert, K., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub3 · Cited by 39
Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China
Gao, F., Zhou, Y. J., Hu, D. Y., Zhao, Y. X., Liu, Y. Y., Wang, Z. J., Yang, S. W., & Liu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0047681 · Cited by 31
Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy††Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.
Nichols, G. A., Ambegaonkar, B. M., Sazonov, V., & Brown, J. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.050 · Cited by 31
The impact of nontraditional lipid profiles on left ventricular geometric abnormalities in general Chinese population
Wang, H., Li, Z., Guo, X., Chen, Y., Chang, Y., Chen, S., & Sun, Y. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0829-x · Cited by 31
Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study
Sondermeijer, B. M., Rana, J. S., Arsenault, B. J., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12129 · Cited by 30
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 39
Safety assessment of the methanol extract of the stem bark of Amphimas pterocarpoides Harms: Acute and subchronic oral toxicity studies in Wistar rats
Tchoumtchoua, J., Mouchili, O. R., Ateba, S. B., Zingue, S., Halabalaki, M., Mbanya, J. C., Skaltsounis, A., & Njamen, D. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.10.003 · Cited by 30
Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a))
Dallmeier, D., & Köenig, W. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.003 · Cited by 32
Effects of Helicobacter pylori eradication on serum lipid levels
Adachi, K., Mishiro, T., Toda, T., Kano, N., Fujihara, H., Mishima, Y., Konishi, A., Mochida, M., Takahashi, K., & Kinoshita, Y. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-88 · Cited by 30
Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D
Basu, A., Bebu, I., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Budoff, M. J., Alaupovic, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p090647 · Cited by 30
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
Statin Effects on Metabolic Profiles
Kofink, D., Eppinga, R. N., van Gilst, W. H., Bakker, S. J. L., Dullaart, R. P. F., van der Harst, P., & Asselbergs, F. W. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001759 · Cited by 32
Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?
von Eckardstein, A. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.6 · Cited by 30
Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 30
Eriosema laurentii De Wild (Leguminosae) methanol extract has estrogenic properties and prevents menopausal symptoms in ovariectomized Wistar rats
Ateba, S. B., Njamen, D., Medjakovic, S., Hobiger, S., Mbanya, J. C., Jungbauer, A., & Krenn, L. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.08.050 · Cited by 28
The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice – Point of view
de Vries, M. A., Klop, B., & Cabezas, M. C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.024 · Cited by 26
Apolipoprotein B/A1 Ratio Is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention
Hua, R., Li, Y., Li, W., Wei, Z., Yuan, Z., & Zhou, J. (2021) · Disease Markers · doi:10.1155/2021/8959019 · Cited by 27
Apolipoprotein B is related to arterial pulse wave velocity in young adults: The Cardiovascular Risk in Young Finns Study
Koivistoinen, T., Hutri‐Kähönen, N., Juonala, M., Kööbi, T., Aatola, H., Lehtimäki, T. J., Viikari, J. S. A., Raitakari, O. T., & Kähönen, M. A. P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.037 · Cited by 27
Apolipoprotein B-to-A1 Ratio as a Predictor of Acute Ischemic Nonembolic Stroke in Elderly Subjects
Kostapanos, M. S., Christogiannis, L. G., Bika, E., Bairaktari, E. T., Goudevenos, J. A., Elisaf, M., & Milionis, H. J. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.09.010 · Cited by 27
Higher Serum Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio Is Associated with Increased Mortality among Incident Peritoneal Dialysis Patients
Noh, H.-W., Jeon, Y., Kim, J., Lee, G. Y., Jeon, S., Kim, K.-Y., Lim, J., Jung, H., Choi, J., Park, S.-H., et al. (2021) · Nutrients · doi:10.3390/nu14010144 · Cited by 26
Water dispersible plant sterol formulation shows improved effect on lipid profile compared to plant sterol esters
Shaghaghi, M. A., Harding, S., & Jones, P. J. H. (2013) · Journal of Functional Foods · doi:10.1016/j.jff.2013.10.017 · Cited by 26
What Is the Role of Advanced Lipoprotein Analysis in Practice?
Robinson, J. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.067 · Cited by 26
Targets for LDL-lowering therapy
Sniderman, A. D. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832ca1d6 · Cited by 26
Cardio-Protective-Promoting Properties of Functional Foods Inducing HDL-Cholesterol Levels and Functionality
Velissaridou, A., Panoutsopoulou, E., Prokopiou, V. D., & Τσούπρας, Α. (2024) · Nutraceuticals · doi:10.3390/nutraceuticals4040028 · Cited by 29
Association of LDL-C/HDL-C ratio with coronary heart disease: A meta-analysis
Hu, S., Fan, H., Zhang, S., Chen, C., You, Y., Wang, C., Li, J., Luo, L., Cheng, Y., Zhou, M., et al. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.014 · Cited by 25
The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population
Jung, C. H., Hwang, J. Y., Yu, J. H., Shin, M. S., Bae, S. J., Park, J., Kim, H., & Lee, W. J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04329.x · Cited by 25
Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis
Vaverková, H., Karásek, D., Novotný, D., Jackuliaková, D., Lukeš, J., Halenka, M., & Frohlich, J. J. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.004 · Cited by 25
Usefulness of Apolipoprotein B/Apolipoprotein A-I Ratio to Predict Coronary Artery Disease Independent of the Metabolic Syndrome in African Americans
Enkhmaa, B., Anuurad, E., Zhang, Z., Pearson, T. A., & Berglund, L. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.056 · Cited by 24
The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies
Manoria, P. C., Chopra, H. K., Parashar, S.-R., Dutta, A. L., Pinto, B., Mullasari, A., & Prajapati, S. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.10.015 · Cited by 27
Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy
Maki, K. C., Dicklin, M. R., Davidson, M. H., Doyle, R. T., & Ballantyne, C. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.063 · Cited by 24
Risk of Atherosclerosis in Patients with Ataxia Telangiectasia
Andrade, I. G. A., Costa‐Carvalho, B. T., da Silva, R., Hix, S., Kochi, C., Suano-Souza, F. I., & Sarni, R. O. S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000430790 · Cited by 24
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?
Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0058 · Cited by 24
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
Robinson, J. G., Ballantyne, C. M., Hsueh, W. A., Rosen, J., Lin, J., Shah, A. K., Lowe, R. S., Hanson, M. E., & Tershakovec, A. M. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.004 · Cited by 23
Apolipoprotein B/A-I Ratio Predicts Lesion Severity and Clinical Outcomes in Diabetic Patients With Acute Coronary Syndrome
Liu, Y., Jia, S., Yuan, D., Xu, N., Jiang, L., Gao, Z., Chen, J., Yang, Y., Gao, R.-L., Xu, B., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1097 · Cited by 23
Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus
Nichols, G. A., Vupputuri, S. X., & Rosales, A. G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.05.047 · Cited by 23
Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering—lipoprotein changes and interactions: the SANDS study
Howard, W. J., Russell, M., Fleg, J. L., Mete, M., Ali, T., Devereux, R. B., Galloway, J. M., Otvos, J. D., Ratner, R. E., Roman, M. J., et al. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.09.001 · Cited by 23
The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
Katsi, V. K., Argyriou, N., Fragoulis, C., & Tsioufis, K. P. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070256 · Cited by 29
The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
Arsenault, B. J., Boekholdt, S. M., Hovingh, G. K., Hyde, C. L., DeMicco, D. A., Chatterjee, A., Barter, P. J., DEEDWANIA, P. C., Waters, D. D., LaRosa, J. C., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960252 · Cited by 22
Synthesis, hypolipidemic, and anti-inflammatory activities of arylphthalimides
Assis, S. P. D. O., Araújo, T. G., Sena, V. L. M., Catanho, M. T. J. A., RAMOS, M. N., Srivastava, R. M., & Lima, V. L. M. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0673-6 · Cited by 22
Lycopene-Rich Extract from Red Guava (Psidium guajava L.) Decreases Plasma Triglycerides and Improves Oxidative Stress Biomarkers on Experimentally-Induced Dyslipidemia in Hamsters
Brito, A. K. D. S., Lima, G. D. M., de Farias, L. M., Rodrigues, L. A. R. L., de Carvalho, V. B. L., Pereira, C. F. D. C., Frota, K. D. M. G., Conde-Júnior, A. M., Silva, A. M. D. O. E., Rizzo, M. D. S., et al. (2019) · Nutrients · doi:10.3390/nu11020393 · Cited by 22
Low‐Density Lipoprotein Levels in Patients With Acute Heart Failure
Kahn, M. R., Kosmas, C. E., Wagman, G., Serrao, G. W., Fallahi, A., Grady, K. M., & Vittorio, T. J. (2012) · Congestive Heart Failure · doi:10.1111/chf.12006 · Cited by 21
Relationship between non–high-density lipoprotein cholesterol and carotid atherosclerosis in normotensive and euglycemic Chinese middle-aged and elderly adults
Ma, H., Lin, H., Hu, Y., Li, X., He, W., Jin, X., Gao, J., Zhao, N., Pan, B., & Gao, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0451-4 · Cited by 21
Low‐Density Lipoprotein Cholesterol/High‐Density Lipoprotein Cholesterol Ratio and Carotid Intima‐Media Thickness: A Cohort Study in China
Qin, P., Shi, J. C., Cao, L., Li, X., Lou, Y., Wang, C., Ma, J., Wang, L., Peng, X., Chen, H., et al. (2020) · Lipids · doi:10.1002/lipd.12274 · Cited by 20
Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases
Sturm, E. M., Knuplez, E., & Marsche, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094377 · Cited by 21
Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?
Baruch, L., Agarwal, S., Gupta, B. P., Haynos, A. F., Johnson, S., Kelly-Johnson, K., & Eng, C. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.05.003 · Cited by 20
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 20

Authors: Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., & Grundy, S. M.
Affiliations: State University of New York (US)
From the Academic Medical Center, University of Amsterdam (J.J.P.K., W.A.v.d.S., S.M.B.), Amsterdam, the Netherlands; Center for Preventive Medicine, Ullevål University Hospital (I.H., T.R.P.), Oslo, Norway; Pfizer Inc (M.G., N.B.C., D.A.D., M.S.), New York, NY; the Heart Research Institute (P.B.), Sydney, Australia; Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine (P.D.), San Francisco, Calif; University Hospital (A.G.O.),...
ORCID: Kastelein, John J.P.
Gaffney, Michael
Cater, Nilo B.
Deedwania, Prakash
Olsson, Anders G.
Boekholdt, S. Matthijs
Demicco, David A.
Szarek, Michael
Pedersen, Terje R.
Grundy, Scott M.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-06-10
Volume: 117
Issue: 23
Pages: 3002-3009
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.107.713438
OpenAlex: W1982036768
Cited by: 478
References: 45
Citations by year: 2026: 10 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 16 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 23 · 2017: 25 · 2016: 14 · 2015: 32 · 2014: 23 · 2013: 36 · 2012: 31
FWCI: 52.34
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: statin therapy, non-HDL cholesterol, apolipoprotein B, apolipoprotein B/A-I ratio, TC/HDL-C ratio, LDL cholesterol, apolipoprotein A-I, cardiovascular events, coronary artery disease, lipid-lowering targets, lipoprotein ratios
MeSH terms: Aged, Apolipoproteins B, Coronary Disease, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Triglycerides, Proportional Hazards Models, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks